Xenon Pharmaceuticals Inc
NASDAQ:XENE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
28.23
45.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Xenon Pharmaceuticals Inc
Cash from Operating Activities
Xenon Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Operating Activities
-$252m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
-32%
|
|
|
Theratechnologies Inc
TSX:TH
|
Cash from Operating Activities
$7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Operating Activities
-$70.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-95%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
$120.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Willow Biosciences Inc
TSX:WLLW
|
Cash from Operating Activities
-CA$2.2m
|
CAGR 3-Years
51%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$9.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-115%
|
CAGR 10-Years
0%
|
|
Xenon Pharmaceuticals Inc
Glance View
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company spotlighted in the arena of precision medicine, with a strategic emphasis on neurological disorders. The company finds its roots in the ethos of innovation, aiming to transform the landscape of treatment through the development of novel therapeutics. At the heart of its operations is a robust platform driven by genetic insights, which allows the company to unearth underlying neurological pathways, thereby targeting diseases that truly lack effective treatment options. Xenon leverages its deep expertise in ion channel biology—vastly important in the function of the nervous system—to design small molecule therapies, positioning itself as a pioneer in addressing complex cerebral disorders such as epilepsy. A key aspect of how Xenon Pharmaceuticals generates revenue is through a dual approach: self-initiated proprietary product development and strategic collaborations with established pharmaceutical giants. Its revenue model is largely propelled by both developmental milestone payments and potential royalties from these alliances. This includes partnerships that allow Xenon to share its innovative platform while receiving financial backing and resources, ensuring the infrastructural strength needed to sustain its clinical programs. By maintaining a pipeline that promises targeted, personalized treatments, Xenon aims not only to meet clinical milestones but to also carve out significant market share within the neuroscience domain, paving its path to profitability and industry impact.
See Also
What is Xenon Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-252m
USD
Based on the financial report for Sep 30, 2025, Xenon Pharmaceuticals Inc's Cash from Operating Activities amounts to -252m USD.
What is Xenon Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-32%
Over the last year, the Cash from Operating Activities growth was -55%. The average annual Cash from Operating Activities growth rates for Xenon Pharmaceuticals Inc have been -43% over the past three years , -75% over the past five years , and -32% over the past ten years .